Skip to main content
logo
Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.6950
-0.0285 (-3.94%)
At close: Oct 2, 2026, 4:00 PM EDT
0.7001
+0.0051 (0.73%)
After-hours: Oct 2, 2026, 7:30 PM EDT

Aprea Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.010.291.50.58--
Revenue Growth
-99.38%-80.98%157.63%---
Cost of Revenue
6.727.049.367.6316.423.9
Gross Profit
-6.72-6.76-7.86-7.04-16.4-23.9
Selling, General & Admin
6.516.486.468.4320.9713.55
Operating Expenses
6.516.486.468.4320.9713.55
Operating Income
-13.22-13.23-14.32-15.47-37.37-37.45
Interest & Investment Income
0.760.651.291.220.450
Currency Exchange Gain (Loss)
-0-0.10.07-0.040.280.32
Other Non Operating Income (Expenses)
0.160.08----
EBT Excluding Unusual Items
-12.31-12.6-12.96-14.29-36.64-37.13
Pretax Income
-12.31-12.6-12.96-14.29-112.66-37.13
Net Income
-12.31-12.6-12.96-14.29-112.66-37.13
Net Income to Common
-12.31-12.6-12.96-14.29-112.66-37.13
Net Income Growth
------
Shares Outstanding (Basic)
2176421
Shares Outstanding (Diluted)
2176421
Shares Change
243.85%18.67%52.31%118.31%55.69%0.72%
EPS (Basic)
-0.60-1.93-2.35-3.95-67.99-34.88
EPS (Diluted)
-0.60-1.93-2.35-3.95-67.99-34.88
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-12.18-12.89-13.57-12.27-25.01-37.69
Free Cash Flow Per Share
-0.59-1.97-2.46-3.39-15.09-35.41
Operating Margin
-255025.52%-4631.12%-953.00%-2652.80%--
Profit Margin
-237362.80%-4409.16%-862.43%-2449.59%--
Free Cash Flow Margin
-234974.18%-4512.35%-903.26%-2103.92%--
EBITDA
-13.2-13.21-14.3-15.46-37.37-37.43
D&A For EBITDA
0.020.020.020.0100.01
EBIT
-13.22-13.23-14.32-15.47-37.37-37.45
SEC Filings: 10-K · 10-Q